EP Patent

EP3057976A1 — Hcv polymerase inhibitors

Assigned to Medivir AB · Expires 2016-08-24 · 10y expired

What this patent protects

The invention provides compounds of the formula (I) wherein B is a nucleobase selected from the groups (a) to (d): and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.

USPTO Abstract

The invention provides compounds of the formula (I) wherein B is a nucleobase selected from the groups (a) to (d): and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.

Drugs covered by this patent

Patent Metadata

Patent number: EP3057976A1
Jurisdiction: EP
Classification: —
Expires: 2016-08-24
Drug substance claim: No
Drug product claim: No
Assignee: Medivir AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.